Cullinan Oncology
CGEM
82 hedge funds and large institutions have $386M invested in Cullinan Oncology in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 5 closing their positions.
179% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $490K
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
9% more funds holding
Funds holding: 75 → 82 (+7)
0.62% less ownership
Funds ownership: 83.28% → 82.66% (-0.62%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
31% less capital invested
Capital invested by funds: $559M → $386M (-$173M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.31M |
| 2 |
CA
CHI Advisors
New York
|
+$3.73M |
| 3 |
Morgan Stanley
New York
|
+$2.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.39M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$2.03M |
| 3 |
O
OrbiMed
New York
|
-$1.81M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.27M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LC
76
Lindbrook Capital
Calabasas,
California
| $2K | +$1.96K | +145 | New |
|
77
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
WTA
78
Washington Trust Advisors
Wellesley,
Massachusetts
| $1K | – | – | – |
|
79
Group One Trading
Chicago,
Illinois
| $1K | +$1.35K | +100 | New |
|
80
Macquarie Group
Sydney, NSW 2000,
Australia
| $12 | – | – | – |
|
81
Renaissance Technologies
New York
| – | -$410K | -26,600 | Closed |
|
82
ProShare Advisors
Bethesda,
Maryland
| – | -$183K | -11,810 | Closed |
|
83
SG Americas Securities
New York
| – | -$168K | -10,916 | Closed |
|
|
DFCM
84
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$158K | -10,214 | Closed |
|
|
PHK
85
Point72 Hong Kong
Hong Kong
| – | -$14K | -929 | Closed |
|
|
PA
86
Parallel Advisors
San Francisco,
California
| – | +$81 | +6 | New |
|
CGEM Hedge Fund Activity: Q1 2022 in Review
82 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2022, worth a combined $386M — down 31% from $559M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CGEM positions and 5 closed out — a net gain of 7 holders — while 22 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.31M. The largest seller was Deerfield Management, cutting an estimated $4M.
- 82 institutional investors held Cullinan Oncology (CGEM) as of Q1 2022, up from 75 in Q4 2021.
- Funds reported $386M of Cullinan Oncology stock for Q1 2022, down 31% quarter-over-quarter.
- 12 funds opened new Cullinan Oncology positions in Q1 2022 and 5 closed out, a net change of +7 holders.
- The largest Cullinan Oncology buyer in Q1 2022 was Fidelity Investments, an estimated $9.31M added.
- The largest Cullinan Oncology seller in Q1 2022 was Deerfield Management, an estimated $4M sold.
Based on aggregated 13F filings for Q1 2022.